Codexis (CDXS) Insider David Smith Buys 66,350 Shares
A group of six insiders picked up identical blocks of stock in Codexis, Inc. on June 17, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
David Smith bought 66,350 shares of Codexis, Inc. ($CDXS) on June 17, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $CDXS is down 8.5% after 1 week, down 9.7% after 1 month and down 50.0% to date (from the $2.48 close on Jun 17, 2026).
CDXS
Codexis, Inc.
Key Points
- Six insiders at Codexis, Inc. acquired 66,350 shares each on June 17, 2026, adding to their stakes in the biotechnology firm.
- The stock trades at $2.57, sitting closer to its yearly high of $2.98 than its low of $0.96 while carrying a market capitalization of roughly $151.1 million.
- Piper Sandler maintains an overweight rating on Codexis with an adjusted price target of $8.00 as the company heads toward its next earnings report on November 5, 2026.
Get $CDXS trade alerts by text
We text you when insiders, Congress or big funds trade $CDXS. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Codexis, Inc. alert may contain errors. Disclosures
Multiple Insiders Pick Up Blocks of Codexis Stock
Codexis, Inc. (NasdaqGS: CDXS) experienced a coordinated wave of insider buying on June 17, 2026, when a group of six different individuals acquired identical blocks of shares. De Vre Raymond, Cynthia Collins, Dilly Stephen George, Esther Martinborough, Rahul Singhvi, and Stewart Parker each purchased 66,350 shares of the biotechnology company on the same day. These transactions expand the personal holdings of several key figures tied to the organization, reflecting renewed alignment between management, board members, and the underlying equity.
Codexis Stock Trades Near Upper End of Yearly Range
Shares of Codexis trade around $2.57, positioning the company well above its 52-week low of $0.96 and close to its yearly high of $2.98. The firm carries a market capitalization of roughly $151.1 million. The equity sits significantly higher than both its 50-day moving average of $1.62 and its 200-day moving average of $1.87, showing strong momentum over recent months.
Piper Sandler Adjusts Price Target Ahead of Earnings
Analyst coverage includes a recent update from Piper Sandler. On August 17, 2026, Piper Sandler maintained its overweight rating on Codexis while lowering its price target from $9.00 to $8.00. Across the broader analyst community, the stock holds a consensus buy recommendation with a target mean price of $6.14, drawing from seven analyst opinions with a high target of $11.00 and a low of $2.00.
Financial Health and Core Operations
Codexis provides technology solutions for therapeutics manufacturing, utilizing its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes. The company also works on its ECO Synthesis manufacturing platform for RNAi therapeutics and maintains key license agreements with partners like Aldevron and Pfizer. Financially, the company reported $77.7 million in revenue over the trailing period, alongside a net margin of negative 39.55% and a return on equity of negative 69.36%. The company maintains a current ratio of 3.06 and a quick ratio of 2.83, pointing to solid short-term liquidity despite ongoing net losses.
What to Watch Next for Codexis
Investors tracking Codexis will look ahead to the next earnings report, scheduled for November 5, 2026, when management is expected to provide further updates on enzymatic manufacturing solutions and platform licensing. Additional Form 4 filings with the SEC will clarify whether this multi-member buying wave is an isolated event or part of a longer accumulation trend by leadership.
Related Filing Alerts
Source: David Smith's Form 4 filing on $CDXS (Jun 17, 2026). Find the original filing: CDXS Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts